KMPHARMACEUTICAL Co (225430) Fair Value & Analysis
Financial Services · KR · Market cap 7.9B KRW
Fair value as of: Jul 22, 2026
From 3 valuation models · updated 19 days ago
Fair value updated Jul 22, 2026, revised from 231.27 KRW to 218.89 KRW (−5.4%) since Jun 26, 2026. Share price +39.8% over the past month.
Below-average quality, and screening another 87% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (261.97 KRW). The favourable scenario is already priced in.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- Solid but not exceptional quality (46/100) and above fair value, neither a clear bargain nor a standout compounder.
- For a financial, book-value and earnings-based methods matter more than a cash-flow DCF, which fits banks and insurers poorly.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.
How to read this chart
60‑month range 1,221 KRW – 15,350 KRW · fair‑value band 176.62 KRW – 261.97 KRW · the 1,711 KRW price screens above the 218.89 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 22, 2026.
Analysis
KMPHARMACEUTICAL Co (225430) currently trades at 1,711 KRW, while our model-based Fair Value estimate is 218.89 KRW, implying the stock looks roughly 87.2% overvalued today. The Quality Score stands at 46/100 (below-average quality), in the Financial Services sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, KMPHARMACEUTICAL Co generated revenue of 16.4B KRW at a net margin of -24.3%. Revenue grew 9.5% year over year. It earns a return on equity of -13.4%. Net debt stands at 15.4B KRW. Fundamentals as of Jul 22, 2026
Our scenario range runs from 176.62 KRW (bear case) to 261.97 KRW (bull case); at 1,711 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 75% below its 52-week high and 2% above its 52-week low, currently below its 200-day average. For context, the median of 10 Financial Services peers we cover trades at -12% fair-value upside, at -87%, 225430 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 3 models by family
Widest divergence: Asset-Based (3,396 KRW) versus Dividend Discount (218.89 KRW). Highest evidence: Gordon GGM (70).
Notify me when 225430 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 45 · Market factors (momentum, volatility) 16
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
KMPHARMACEUTICAL Co.,Ltd. engages in the manufacture, wholesale, and retail of oral care, beauty care, and other daily necessities in South Korea and internationally. The company offers toothpastes, toothbrushes, cosmetics, masks, hand cream, toothbrush and toothpaste, kids toothbrush, and baby finger toothbrush sets.
Full company description
KMPHARMACEUTICAL Co.,Ltd. engages in the manufacture, wholesale, and retail of oral care, beauty care, and other daily necessities in South Korea and internationally. The company offers toothpastes, toothbrushes, cosmetics, masks, hand cream, toothbrush and toothpaste, kids toothbrush, and baby finger toothbrush sets. It also provides children's safety gargles, baby and light wipes, wet wipes, and steam eye masks; shampoos, body washes, sun creams, moisture creams, wrinkle functional cosmetics, and hair dyes; and dehumidifiers and hand sanitizers. The company was founded in 2001 and is headquartered in Pyeongtaek-si, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
KMPHARMACEUTICAL Co reported revenue of 16.0B KRW in FY2025 versus 22.7B KRW in FY2021, a compound −8.4%/yr. Reported net income was −4.0B KRW in FY2025.
225430 screens 87% overvalued. Compare with Fondul Proprietatea SA →
Peer Group
Asset Management · 971 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Asset Management stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Fondul Proprietatea SA FP | $0.0420 | $0.0800 | +90% |
| BlackRock, Inc BLK | $1,136 | $465.75 | -59% |
| Blackstone Inc BX | $124.56 | $16.35 | -87% |
| Investor AB INVEB | kr 423.70 | kr 847.40 | +100% |
| Brookfield Corporation BN | C$62.45 | C$10.12 | -84% |
| KKR & Co KKR | $100.94 | $44.88 | -56% |
| AB Industrivärden INDUA | kr 532.50 | kr 1,065 | +100% |
| Jio Financial Services Limited JIOFIN | ₹242.98 | ₹40.19 | -83% |
| Hedef Holding HEDEF | 267.25 TRY | 320.98 TRY | +20% |
| Bajaj Holdings BAJAJHLDNG | ₹10,398 | ₹9,202 | -12% |
Compare KMPHARMACEUTICAL Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Financial Services stocks →
Frequently asked questions
Is KMPHARMACEUTICAL Co (225430) overvalued or undervalued?
What is the fair value of 225430?
What is the quality score of 225430?
What is the revenue of KMPHARMACEUTICAL Co (225430)?
What is the net profit margin of 225430?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track KMPHARMACEUTICAL Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.